Select Publications

Dowsett M et al. Risk of distant recurrence using Oncotype DX in postmenopausal
primary breast cancer patients treated with anastrozole or tamoxifen: A TransATAC study. Presentation. San Antonio Breast Cancer Symposium 2008;Abstract 53.

Rasmussen BB et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: Supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008;9(1):23-8. Abstract

Viale G et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;26(34):5569-75. Abstract

Viale G et al. Prognostic and predictive value of centrally reviewed expression of
estrogen and progesterone receptors in a randomized trial comparing letrozole and
tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007;25(25):3846-52. Abstract

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Home · Search

EDITOR
Neil Love, MD

INTERVIEWS

Harold J Burstein, MD, PhD
- Select publications

Jack Cuzick, PhD
- Select publications

Howard A Burris III, MD
- Select publications

Mark D Pegram, MD
- Select publications

 

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office